Icon

VYVANSE (nda021977)- (10MG,20MG,30MG,40MG,50MG,60MG,70MG)

LISDEXAMFETAMINE DIMESYLATE TAKEDA PHARMS USA
10MG,20MG,30MG,40MG,50MG,60MG,70MG
Yes No
2023-Aug-24 2012-Feb-23
None None
None No
VYVANSE is a central nervous system (CNS) stimulant indicated for the treatment of: • Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older • Moderate to severe binge eating disorder (BED) in adults
15 0 10
Total Other Developers 2
Drugs with Suitability No
10MG ** ** Up - 8
20MG ** ** Up 8 2
30MG ** ** Up 8 2
40MG ** ** Up 8 2
50MG ** ** Up 8 2
60MG ** ** Up 8 2
70MG ** ** Up 8 2
NDA Sales Available Total Generic Sales Available
Yes 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** **** ************** *** *********** ** ***** ********* **, ********, *** ****** (**) *****, ****** ****** (***) ***
****** ****** ******** ********, *** *********** **** ******** ******, ************, ************ (**) *****, ****** ****** (***) ***
****** ******** *** ******** ***** ** *** */*/* ******** ************ *********** **** ******** ****., *********, ***** ******** (**) *****, ****** ****** (***) ***
****** ****** ****** *** ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** *** ***** **** *** *** ************ ***. *********** ** ******** ****, *** *********, *** ****** (**) *****, ****** ****** (***) ***
****** ****** *** ****** *** *********** *** ******** ****** *.*. *** *, ******, *** **** (**) *****, ****** ****** (***) ***
****** ****** ****** ****** *************** *.*. *********** **** ************* **** *, ******, ***** ******** (**) *****, ****** ****** (***) ***
****** ***** ****-**** ******** ***. *********** **** ****** ****, ********, **** (**) *****, ****** ****** (***) ***
****** ****** ****** *************** ** *** ****, *** *********** ** ***** ***, *********, *** **** (**) *****-****, ****** ****** (***) ***
****** ****** ****** *************** ** *** ****, *** *********** ** ********** **, **********, *** **** (**) *****-****, ****** ****** (***) ***
****** ******* ******* ***************, ***. *********** **** ***** ******* **, *******, *** **** (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.